Meiji Yasuda Asset Management Co Ltd. Makes New Investment in Illumina, Inc. $ILMN

Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 4,890 shares of the life sciences company’s stock, valued at approximately $860,000.

A number of other hedge funds have also modified their holdings of ILMN. Empowered Funds LLC grew its position in Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Illumina in the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new stake in Illumina during the 2nd quarter worth $275,000. Marshall Wace LLP boosted its position in Illumina by 49.0% during the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the last quarter. Finally, Cresset Asset Management LLC grew its position in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares in the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the subject of a number of analyst reports. Stifel Nicolaus upped their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a report on Friday, July 31st. Zacks Research upgraded Illumina from a “hold” rating to a “strong-buy” rating in a report on Monday, August 3rd. TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Canaccord Genuity Group lifted their price objective on Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research note on Monday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Stock Up 0.8%

Illumina stock opened at $224.99 on Wednesday. The company has a market capitalization of $33.97 billion, a P/E ratio of 41.98, a PEG ratio of 3.14 and a beta of 1.45. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $226.84. The stock has a 50-day simple moving average of $190.35 and a 200-day simple moving average of $153.78. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same period last year, the firm posted $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 299,336 shares of the stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $217.96, for a total transaction of $65,243,274.56. Following the completion of the sale, the director owned 1,409,851 shares in the company, valued at approximately $307,291,123.96. This represents a 17.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider directly owned 20,338 shares in the company, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,095,958 shares of company stock worth $401,720,974 over the last three months. 2.90% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.